March 2023 Disclaimer This presentation (together with oral statements made in connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sell, or the

Disclaimer This presentation (together with oral statements made in

connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in

any states or jurisdictions in which such offer, solicitation or sale would be unlawful. Forward Looking Statements Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the

safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will,"

"estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem,"

"seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited

to, statements by NewAmsterdam Pharma Company N.V. ("NewAmsterdam" or the "Company") regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity; expectations and timing

related to the success, cost and timing of product development activities, including timing of initiation, completion and data readouts for clinical trials and the potential approval of the Company's product candidate; the size and growth

potential of the markets for the Company's product candidate; the therapeutic and curative potential of the Company's product candidate; financing and other business milestones; and the Company's expected cash runway. These

statements are based on various assumptions, whether or not identified in this Presentation, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are

provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or

impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and

foreign business, market, financial, political, and legal conditions; risks related to the approval of NewAmsterdam's product candidate and the timing of expected regulatory and business milestones; ability to negotiate definitive contractual

arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; the impact of COVID-19; global economic and political conditions, including the Russia-Ukraine conflict; the

effects of competition on NewAmsterdam's future business; and those factors discussed in documents filed by the Company with the SEC. Additional risks related to NewAmsterdam's business include, but are not limited to: uncertainty

regarding outcomes of the company's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with the Company's efforts to commercialize a product

candidate; the Company's ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the Company's business; intellectual property-related claims; the

Company's ability to attract and retain qualified personnel; and the Company's ability to continue to source the raw materials for its product candidate, together with the risks described in the Company's filings made with the U.S.

Securities and Exchange Commission from time to time. If any of these risks materialize or NewAmsterdam's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There

may be additional risks that are presently unknown by the Company or that NewAmsterdam currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition,

forward-looking statements reflect NewAmsterdam's expectations, plans, or forecasts of future events and views as of the date of this Presentation and are quali ed in their entirety by reference to the cautionary statements herein.

NewAmsterdam anticipates that subsequent events and developments will cause the Company's assessments to change. These forward-looking statements should not be relied upon as representing NewAmsterdam's assessments as of any date

subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither NewAmsterdam nor any of its affiliates undertakes any obligation to update these forward-looking statements,

except as required by law. Market Data Certain information contained in this Presentation relates to or is based on third-party studies, publications, surveys and NewAmsterdam's own internal estimates and research. In addition, all of the

market data included in this Presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while NewAmsterdam believes its internal research is reliable,

such research has not been verified by any independent source and NewAmsterdam cannot guarantee and makes no representation or warranty, express or implied, as to its accuracy and completeness. Trademarks This Presentation contains trademarks,

service marks, trade names, and copyrights of NewAmsterdam and other companies, which are the property of their respective owners. The use or display of third parties' trademarks, service marks, trade name or products in this Presentation is

not intended to, and does not imply, a relationship with NewAmsterdam or an endorsement or sponsorship by or of NewAmsterdam. Solely for convenience, the trademarks, service marks and trade names referred to in this Presentation may appear with the

TM or SM symbols, but such references are not intended to indicate, in any way, that NewAmsterdam will not assert, to the fullest extent permitted under applicable law, their rights or the right of the applicable licensor to these trademarks,

service marks and trade names. 2 PROPRIETARY

NewAmsterdam is developing oral obicetrapib as CETPi to address major

unmet need in hypercholesterolemia and other cardiometabolic diseases O B I C E T RA P I B Company history: Achievements and milestones: Significant unmet need for oral LDL-lowering therapy as adjunct to statins: 35mm+ patients in US/EU5 are

not achieving LDL-lowering goals despite Mid-'20: Founded after standard-of-care Fully-funded through 2026 spin-out from Amgen including CVOT readout and Simple, oral, once-daily, low dose CETP inhibitor with strong

LDL-lowering potential global launch Jan '21: $196M Series A efficacy and safety observed through Phase 2b: Significant number of June '22: >$1B European ~50% LDL-lowering as monotherapy, ~59% in

combination with ezetimibe, patients randomized in Phase 3 license with Menarini Group observed on top of high-intensity statins to-date, first DSMB meeting (including 142.5M committed completed Strong safety and tolerability in

>700 pts capital + significant back-end economics) Robust effects on ApoB, non-HDL-C, HDL-C and Lp(a) Late-stage inflection points expected from 2023-2025 Nov '22: NASDAQ listing Convenient oral format + low

cost of goods sold (COGS) enables broad (including Phase 2 & 3 clinical (NAMS) with $328M total readouts and registrational market access strategy to address existing unmet need proceeds ($93M from FLAC trust filings) in deSPAC, plus $235M PIPE

co- lead by Frazier and Bain) Pipeline expansion potential >35M ~59% in Alzheimer's disease and $4B+ Jan '23: ~$1B market cap addressable LDL-lowering diabetes global market and $450M cash patient observed in

opportunity population Phase 2b 3 PROPRIETARY

Expert cardiometabolic leadership supported by top investors Michael

Davidson, M.D. John Kastelein, M.D. Douglas Kling Lina Gugucheva Louise Kooij Marc Ditmarsch, M.D. CEO CSO COO CBO CFO CDO SANDER SLOOTWEG JULIET JAMIE NICHOLAS LOU MICHAEL DAVIDSON JOHN JOHN W. SEASONED BOARD AUDET TOPPER DOWNING LANGE KASTELEIN

SMITHER OF Managing Partner, Partner, Managing Partner, Partner, Partner, CEO, NewAmsterdam CSO, NewAmsterdam Independent DIRECTORS: Forbion Forbion Frazier Life Sciences Bain Capital Asset Management Pharma Pharma Ventures BACKED BY TOP TIER

INVESTORS: 4 PROPRIETARY

Net proceeds expected to fund obicetrapib development through several

value-creating milestones 2023 2022 2023 2024 2025 2026 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H Phase 3 BROADWAY Trial Lipid Mono Study BROADWAY Ph3 LDL (ASCVD; LDL-C 55 mg/dL; n=2,400) regulatory filing Phase 3 BROOKLYN Trial BROOKLYN Ph3 Lipid Mono

Study (HeFH; LDL-C 70 mg/dL; HeFH; n=300) Obicetrapib MACE Monotherapy Phase 3 CVOT PREVAIL Trial PREVAIL CVOT regulatory Product (ASCVD or HeFH; LDL-C 70 mg/dL; n=9,000) filing (obicetrapib 10mg) Phase 2b Japan Trial Japan Ph2b

(LDL-C 70 mg/dL; n=100) Phase 2b ROSE2 Trial ROSE2 Ph2b LEGEND Ezetimibe FDC (LDL-C 70 mg/dL; n=114) Product Initiation (obicetrapib 10mg + Phase 3 FDC Trial ezetimibe 10mg) FDC Ph3 Enrollment complete (LDL-C 70 mg/dL; n=XXX)

Ph3 readout CVOT readout Alzheimer's Phase 2a Alzheimer's Product Disease Trial Alzheimer's Ph2a Ph2 readout (proprietary (n=10-15) dose/formulation incorporating obicetrapib) PROJECTED CASH RUNWAY THROUGH 2026 Numerous

catalysts throughout 2023 5 Note: Other than as noted, the pipeline represents trials that are currently ongoing. Projections are subject to inherent limitations. Actual results may differ from expectations. The timing of regulatory submissions is

subject to additional discussions PROPRIETARY with regulators. Neuro- Cardiovascular metabolic

Obicetrapib for Cardiovascular Disease 6

Despite availability of statins, CVD remains the leading cause of death

worldwide (1) 231 million Adults in US/EU5 with hypercholesterolemia LDL-C goals (2) 84 million removed in Treated with prescription medication 2013 <1 million post-statin (4) (3) (3) 8 million 22 million patients treated with Statin- Still above

current branded options intolerant LDL-C target Male deaths Female deaths 30 million* ~5 million** Patients with US ASCVD patients w/ 55-70mgl/dl residual need Year Key factors limiting penetration include product limitations and market access

hurdles Despite statins, CVD deaths on the rise **Factoring in new U.S. guidance lowering LDL-C goals to 55 mg/dL for very high-risk patients, which will grow addressable patient population Sources: Trinity NewAmsterdam Market Research Summary;

Trinity quantitative market research with N = 100 PCPs and Cardiologists; Bloomberg Prescription Data; IQVIA Rx Tracker. (1) Literature review suggesting hypercholesterolemia prevalence of ~94mm in the US (average of He et al. 2020, Mercado et al.

2015, Muntner et al. 2013) and ~137mm in EU5 (average of Gomez-Huelgas et al. 2010, Guallar-Castillon et al. 2012, Tragni et al. 2012, Grau et al. 2011). (2) 2020 US prescription data for statins, PCSK9s, and bempedoic acid were pulled from the

Bloomberg Prescription Data Portal that Trinity subscribes to; assuming 12 scripts/year per patient and 70% compliance for PCSK9s (based on PCSK9 literature) and 59% compliance for statins & Nex/Nex (based on statin literature) treated patient

volume estimates were derived from the prescription data and extrapolated to the EU5. (3) 8mm statin-intolerant & 22mm above LDL-C target: Percentage of patients in each category estimated from Trinity quantitative market research and the

- percentages were then applied to the estimated 84mm treated number above. 7 (4) <1mm branded patients: 2020 US prescription data for Repatha, Praluent, and Nexletol/Nexlizet were pulled from the Bloomberg Prescription Data Portal that

Trinity subscribes to; assuming 12 scripts/year and 70% compliance for PCSK9s (based on PROPRIETARY PCSK9 literature) and 59% compliance for Nex/Nex (based on statin literature) patient volume estimates were derived from the prescription data and

extrapolated to the EU5. Deaths in Thousands

Cardiovascular field is returning to the mantra of "Lower is

Better", as supported by recently published FOURIER-OLE analysis In patients with atherosclerotic cardiovascular disease, long-term achievement of lower LDL-C levels, down to <20 mg/dL (<0.5 mmol/L), was associated with lowest of

cardiovascular outcomes compared to patients who achieved less robust LDL- C reduction Risk of CV death, MI, stroke 70 LDL-C 55- 70 LDL-C Achieved LDL-C 40- 55 LDL-C 20 LDL-C Composite of cardiovascular death, myocardial

infarction, or stroke from FOURIER-OLE (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-Label Extension) p-value = 0.0001 Time post-enrollment (years) Note: Gaba P, et. al., Association Between

Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023 Feb 13. doi: 10.1161/CIRCULATIONAHA.122.063399 PROPRIETARY 8 Cumulative incidence rate (%)

Currently approved post-statin LDL-lowering products all fall short of

the profile patients need Patients need a drug that fits Ezetimibe Nexletol PCSK9 the following profile: (1) (1) Modest Modest Strong Strong Efficacy Oral, Oral, Injectable, Oral, Low Dose High Dose High Dose Administration/ 10mg 180mg ~140-150mg

Low Dose Dose Disruptive Price, Very High Price, Generic, Branded Price, Market Access/Price Highly Restricted Access Broad Access Broad Access Limited Access (High COGS) (Low COGS) Safe, Safe, FDA Label: Safe Safety & Tolerability Tendon

rupture & gout warning Painful injection site reactions Well Tolerated Well-Tolerated Strong Lp(a) Lowering, HDL Raising has Potential Ancillary None None Modest Lp(a) Lowering Benefits in Alzheimer's and Benefit(s) Diabetes Note:

Novartis' stated price of Inclisiran to be approximate to net prices of PCSK9 mAbs. (1) Lighter shaded region of bar chart represents the additional potential efficacy for fixed dose combinations with ezetimibe. 9 PROPRIETARY

~50% LDL-C reduction efficacy would be virtually identical to PCSK9

injectables and is substantially better than other oral therapies Cross trial comparison of LDL-C reduction across different approaches (in %) Obicetrapib Anacetrapib Evacetrapib Dalcetrapib Ezetimibe Nexletol Repatha Praluent Leqvio * 1 2 3 4 5 6 7

8 10mg 100mg 130mg 600mg 10mg 180mg 420mg 150mg 284mg 0 -7 -10 -15 -17 -20 -21 -25 -30 There is Obicetrapib currently -40 mono dose no approved observed to oral drug with reduce LDL-C LDL-lowering by 51% in -46 -47 potency in the Phase 2b -50 50%

range -51 Obicetrapib + ezetimibe combo shown to reduce -60 Prior CETP inhibitors Existing oral therapies PCSK9 injectables LDL by ~59% in Ezetimibe is generic, Nexletol bears FDA label Phase 2b for tendon rupture, gout The trials represented were

selected due to their shared features that reflect the Phase 3 obicetrapib studies. Selecting trials with shared features allows for a potentially more accurate comparison of the LDL-C lowering results, with factors being considered such as: a)

presence of intensive LDL-lowering therapy including (high intensity) statins and PCSK9 inhibitors, b) patient population - ASCVD or ASCVD risk equivalent patients (including primary hypercholesterolemia and HefH) and c) where possible,

selected studies where LDL-C measured by preparative ultracentrifugation (PUC ) as opposed to Friedewald; noted below are those instances where PUC was not used - this is important because at low LDL-C levels (< 50 mg/dL), calculated LDL-C

by Friedewald is overestimated; certain significant deviations from these parameters are provided in the footnotes. Note: The above trials and data do not represent head-to-head comparisons. Actual results may differ from expectations. Sources: *

Circulation. 2021;144:e564-e593 17065. 1. Bowman, L et al. N Engl J Med 2017. 2. Amirhossein, S et al. Curr Pharmaceutical Design 2016. Meta-analysis - Also included hyperlipidaemia patients. LDL-C measured using direct assays and Friedewald.

3. de Grooth et al. Circulation 2002. LDL-C measured only using Friedewald and did not require subjects to be on prior statin therapy or present with ASCVD. 4. PI Zetia table 7. refers to; Gagne, C et al. Am J Cardiol 2002. LDL-C measured only using

Friedewald. 5. PI Nexletol; study 2. refers to; Goldberg, A et al. JAMA 2019;322(18):1780-1788. LDL-C measured using Friedewald and direct assay for LDL-C <50 mg/dL. 6. PI Repatha; study 3. refers to; Blom, D et al. N Engl J Med 2014. Also 10

PROPRIETARY included hyperlipidaemia patients. 7. PI Praluent; study 3. refers to; Kereiakes, D et al. Am Heart J 2015. 8. PI Leqvio; study 1. Refers to; Ray, K. N Engl J Med 2020. % LDL-C change versus baseline

Obicetrapib has potential to be ideal complement to statin therapy

STATINS STATINS LDL-C + Lp(a) Diabetes STATINS ApoB risk effects Lowering + OBI OBI OBI = finally achieve 55 mg/dl LDL goal CETPi has been shown clinically to Obicetrapib's robust Lp(a)-lowering Obicetrapib's LDL and ApoB lowering

reverse diabetes risk, potentially effect (~57% lowering seen in P2) potency may finally take statin patients ameliorating key patient concerns counter-acts Lp(a)-raising effect to goal about high dose statins observed with statins 11 PROPRIETARY

Obicetrapib has potential to solve a substantial unmet medical need in

dyslipidemia (1) 231mm Patients with >35mm patients not sufficiently addressed by available treatment options hyperlipidemia OBICETRAPIB Fewer than 1mm patients treated with 10mg current branded options: ~50% LDL-lowering observed for

monotherapy, ~59% in combination with ezetimibe in Phase 2b 180mg Potential for attractive pricing to unlock broad Bempedoic Acid PCSK9s access THE SOLUTION Strong safety and tolerability profile observed o Payors highly restrict

access THE Convenient once-daily oral tablet o Low prescriber enthusiasm PROBLEM High prescriber and payor enthusiasm o Relatively low patient compliance (2) >$4B global market opportunity (1) Literature review suggesting

hypercholesterolemia prevalence of ~94mm in the US (average of He et al. 2020, Mercado et al. 2015, Muntner et al. 2013) and ~137mm in EU5 (average of Gomez-Huelgas et al. 2010, Guallar-Castillon et al. 2012, Tragni et al. 2012, Grau et al. 2011).

12 PROPRIETARY (2) Value derived from top-down epidemiology-based market model for obicetrapib; assumptions derived from secondary research / literature and primary market research with US and EU5 physicians and payers.

US market research indicates strong prescriber and payor enthusiasm,

wide window of pricing opportunity to enable broad market access strategy Strong enthusiasm from prescribers Broad market access opportunity: and payors: Market access hurdles plague existing brands: PRESCRIBER ENTHUSIAM: "There is a lot of

documentation involved as Nexletol PCSK9i Obicetrapib $$$$ we're really trying to restrict to the highest PRICE IS TOO HIGH risk patients that actually need these costly for meaningful access (~$6K) products" Efficacy Moderate/Low* High

High -Payor $$$ MODEST EFFICACY, comparable to generics, Safety/ Moderate High High Tolerability make any branded price hard to justify (~$4K) Route of High Low High Administration Obicetrapib positioned to unlock significantly better access:

Low COGS enables favorable pricing PAYOR ENTHUSIAM: Strong LDL-C lowering, virtually same as injectables $$ "Biggest need (is) a product that works like the PCSK9s but with a more Simple, convenient oral pill gives payors

confidence around patient convenient ROA and no diabetes risk" compliance Ancillary benefits for diabetes prevention, Lp(a) lowering "Fulfills an important unmet need" Key: Blue cells denote high ratings (6.5 - 9) /

Yellow cells denote moderate ratings (5 - 6.4) / Red cells denote lowest ratings (1 - 4.9); ratings were given on a 9-point scale, thus lower / red ratings actually reflect the ~midpoint of the scale. *In our survey, obicetrapib mono